ProShare Advisors LLC Has $895,000 Stake in Exelixis, Inc. (NASDAQ:EXEL)

ProShare Advisors LLC reduced its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 8.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 26,886 shares of the biotechnology company’s stock after selling 2,406 shares during the quarter. ProShare Advisors LLC’s holdings in Exelixis were worth $895,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of EXEL. Quantinno Capital Management LP bought a new stake in shares of Exelixis during the fourth quarter worth $559,000. Mubadala Investment Co PJSC acquired a new position in shares of Exelixis during the 4th quarter worth about $2,317,000. Lazard Asset Management LLC lifted its holdings in shares of Exelixis by 80.0% during the 4th quarter. Lazard Asset Management LLC now owns 214,462 shares of the biotechnology company’s stock valued at $7,140,000 after purchasing an additional 95,315 shares in the last quarter. Laird Norton Wetherby Wealth Management LLC bought a new position in shares of Exelixis during the 4th quarter valued at about $234,000. Finally, Janus Henderson Group PLC lifted its holdings in shares of Exelixis by 1.3% during the 4th quarter. Janus Henderson Group PLC now owns 124,905 shares of the biotechnology company’s stock valued at $4,160,000 after purchasing an additional 1,558 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Stock Down 1.1%

NASDAQ:EXEL opened at $42.39 on Friday. The stock’s 50-day simple moving average is $37.91 and its 200 day simple moving average is $36.14. The firm has a market capitalization of $11.56 billion, a PE ratio of 23.95, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $48.85.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on EXEL shares. Barclays upped their price target on Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. JMP Securities reiterated a “market outperform” rating and set a $41.00 price objective on shares of Exelixis in a research note on Thursday, April 17th. Wells Fargo & Company reissued a “market outperform” rating on shares of Exelixis in a report on Thursday, April 17th. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $41.00 to $33.00 in a report on Friday, January 24th. Finally, Guggenheim set a $45.00 price objective on Exelixis and gave the company a “buy” rating in a report on Thursday, May 15th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.94.

Insider Activity at Exelixis

In related news, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the transaction, the chief financial officer now directly owns 779,607 shares of the company’s stock, valued at $28,174,996.98. The trade was a 3.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 126,383 shares of Exelixis stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $47.96, for a total value of $6,061,328.68. Following the completion of the transaction, the executive vice president now directly owns 446,459 shares in the company, valued at approximately $21,412,173.64. This represents a 22.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 559,873 shares of company stock valued at $24,646,347 over the last ninety days. 2.82% of the stock is owned by corporate insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.